Васюк Ю. А., Школьник Е. Л. Cтарые принципы – новые горизонты в лечении ишемической болезни сердца. Кардиоваскулярная терапия и профилактика. 2007;6(1):92-98.
1. Sigh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Therap 2001; 6: 313-31.
2. Wilhelmsen L, Berlund G, Elmfeldt D, et al. The multifactor primary prevention trial in Geteborg, Sweden. Eur Heart J 1986; 7: 279-88.
3. Шальнова С.В., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005; 10: 45-50.
4. Beere P, Glagov S, Zarins C. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-2.
5. Zagotta WN, Olivier NB, Black KD, et al. Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature 2003; 425: 200-5.
6. Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparation: comparison with UL-FS49. Br J Pharmacol 1994; 112: 37-42.
7. Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effects of ivabradine, a selective heart rate reducing agent, in exercise induced myocardial ischemia in pigs. J Cardiovascular Pharmacol 2003; 42: 688-96.
8. Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659-66.
9. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective lf current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109: 1674-9.
10. Borer JD, Fox K, Jaillon P, et al. Antianginal and anti-ischemic effects of ivabradine, an lf inhibitor in stable angina. Circulation 2003; 107: 817-23.
11. Tardif J, Ford I, Tendera M, et al. On behalf of the INITIATIVE study investigators group. Antianginal and anti-ischemic effects of the lf current inhibitor ivabradine compared to athenolol as monotherapies in patients with chronic stable angina. Eur Heart J 2003; 24:Abstract 186.23.
12. Ruzyllo W, Ford I, Tendera M, et al. Antianginal and anti- ischemic effects of the lf current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: A 3-month randomized, controlled, double-blind, multi-center trial. Eur Heart J 2004; 25: Abstract 878.
13. Lopez-Bescos L. Long-term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. Eur Heart J 2004; 25: Abstract 876.
14. Moosmang S, Steiber J, Zong W, et al. Cellular expression and functional characterization of four hyperpolarisation – activated pacemaker cannels in cardiac and neuronal tissues. Eur J Biochem 2001; 268: 1646-52.
